Literature DB >> 11348533

Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis.

J Blum1, S Nkunku, C Burri.   

Abstract

Encephalopathies are the most feared complications of sleeping sickness treatment with melarsoprol. To investigate the existence of risk factors, the incidence of encephalopathic syndromes and the relationship between the development of different types of encephalopathies and the clinical outcome was studied in a clinical trial with 588 patients under treatment with melarsoprol. The 38 encephalopathy cases were classified into three types according to the leading clinical picture: coma type, convulsion type and psychotic reactions. Nine patients were attributed to the convulsion type, defined as a transient event of short duration with convulsions followed by a post-ictal phase, without signs of a generalized disease. None of these patients died from the reaction. Febrile reactions in the 48 h preceding the reaction were generally not observed in this group. Twenty-five patients were attributed to the coma type, which is a progredient coma lasting several days. Those patients often had signs of a generalized disease such as fever (84%), headache (72%) or bullous skin (8%) reactions. The risk of mortality was high in this group (52%). About 14/16 patients with encephalopathic syndrome of the coma type were infected with malaria. Patients with psychotic reactions or abnormal psychiatric behaviour (3/38) and one patient who died after alcohol intake were excluded from the analysis. The overall rate of encephalopathic syndromes in the cases analysed (n=34) was 5.8%, of which 38.2% died. We did not find any parameters of predictive value for the risk of developing an encephalopathic syndrome based on the symptoms and signs before treatment initiation. The appearance during treatment of febrile reactions (RR 11.5), headache (RR 2.5), bullous eruptions (RR 4.5) and systolic hypotension (RR 2.6) were associated with an increased risk for the occurrence of encephalopathic syndromes especially of the coma type.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11348533     DOI: 10.1046/j.1365-3156.2001.00710.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  34 in total

1.  Discovery and verification of osteopontin and Beta-2-microglobulin as promising markers for staging human African trypanosomiasis.

Authors:  Natalia Tiberti; Alexandre Hainard; Veerle Lejon; Xavier Robin; Dieudonné Mumba Ngoyi; Natacha Turck; Enock Matovu; John Enyaru; Joseph Mathu Ndung'u; Alexander Scherl; Loïc Dayon; Jean-Charles Sanchez
Journal:  Mol Cell Proteomics       Date:  2010-08-19       Impact factor: 5.911

Review 2.  Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis.

Authors:  Melanie Walker; James G Kublin; Joseph R Zunt
Journal:  Clin Infect Dis       Date:  2005-11-23       Impact factor: 9.079

Review 3.  Tissue Parasites in HIV Infection.

Authors:  Eva H Clark; Jose A Serpa
Journal:  Curr Infect Dis Rep       Date:  2019-11-16       Impact factor: 3.725

Review 4.  Human African trypanosomiasis in endemic populations and travellers.

Authors:  J A Blum; A L Neumayr; C F Hatz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-07       Impact factor: 3.267

5.  A search for Trypanosoma brucei rhodesiense diagnostic antigens by proteomic screening and targeted cloning.

Authors:  Theresa Manful; Julius Mulindwa; Fernanda M Frank; Christine E Clayton; Enock Matovu
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

6.  Computer-aided identification of Trypanosoma brucei uridine diphosphate galactose 4'-epimerase inhibitors: toward the development of novel therapies for African sleeping sickness.

Authors:  Jacob D Durrant; Michael D Urbaniak; Michael A J Ferguson; J Andrew McCammon
Journal:  J Med Chem       Date:  2010-07-08       Impact factor: 7.446

Review 7.  Pain management in neurocritical care.

Authors:  Axel Petzold; Armand Girbes
Journal:  Neurocrit Care       Date:  2013-10       Impact factor: 3.210

Review 8.  Human African trypanosomiasis: pharmacological re-engagement with a neglected disease.

Authors:  M P Barrett; D W Boykin; R Brun; R R Tidwell
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

9.  Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis.

Authors:  Jose R Franco; Pere P Simarro; Abdoulaye Diarra; Jose A Ruiz-Postigo; Mireille Samo; Jean G Jannin
Journal:  Res Rep Trop Med       Date:  2012-08-23

Review 10.  The natural progression of Gambiense sleeping sickness: what is the evidence?

Authors:  Francesco Checchi; João A N Filipe; Michael P Barrett; Daniel Chandramohan
Journal:  PLoS Negl Trop Dis       Date:  2008-12-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.